Purchase this article with an account.
Shigeru Kinoshita; Update on the clinical trial using cultivated corneal endothelial cell injection. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2003. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Understanding the biological and immunological characteristics of human corneal endothelial cells (hCECs) is an essential key to the establishment of new strategies for treating corneal endothelial dysfunction. In this direction, our research group has been developing a ‘cultured hCEC-injection therapy’ involving the injection of cultured human CECs into the anterior chamber of bullous keratopathy, which may be a completely new strategy of the treatment. For this purpose, non-proliferative corneal endothelial cells from donated corneas have been induced to proliferate, without inducing cell state transition (CST). Our findings have shown this approach to be promising. In order to apply this novel approach to actual clinical practice, several key safety issues must be addressed and assured from the aspect of regulatory science.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only